Clinical Trial Update: Study of a New Generation Botulinum Toxin A2NTX to Treat Spasticity After Stroke [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on a new-generation botulinum toxin A2NTX for post-stroke lower limb spasticity, currently in Phase 2/3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-stroke Spasticity

Drugs mentioned

• A2NTX (botulinum toxin type A2NTX)

Snippet

Sponsor: University of Tokushima | Conditions: Lower Limb Spasticity After Stroke | Phase 2, Phase 3 | Status: UNKNOWN